Concepedia

Publication | Closed Access

A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule

DOI

20

Citations

28

References

2025

Year

Annemie Deiteren, Emmanuel Krupka, Lieselot Bontinck, Karine Imberdis, Griet Conickx, Selçuk Bas, Naimish Patel, Heribert Staudinger, Benjamin T. Suratt
European Respiratory Journal

Abstract

A single dose of lunsekimig was well tolerated, significantly suppressed T2 inflammation and improved lung function in mild-to-moderate asthma.

References

YearCitations

Page 1